Compare Stocks

Comparative Price Performance Over Time

Compare Stocks - Price & Volume

CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
Acer Therapeutics Inc. stock logo
ACER
Acer Therapeutics
$0.66
-17.9%
$0.74
$0.55
$4.56
$16.15M0.21N/A574,600 shs
AgeX Therapeutics, Inc. stock logo
AGE
AgeX Therapeutics
$3.89
$11.07
$35.71
$11.99M1.183,849 shs3,700 shs
Guardion Health Sciences, Inc. stock logo
GHSI
Guardion Health Sciences
$7.90
-3.1%
$8.39
$5.01
$10.75
$10.11M0.88170,891 shs3,146 shs
Hoth Therapeutics, Inc. stock logo
HOTH
Hoth Therapeutics
$1.18
+0.9%
$1.31
$0.99
$4.30
$5.77M0.63388,497 shs48,864 shs
Abliva AB (publ) stock logo
NEVPF
Abliva AB (publ)
$0.01
$0.01
$0.01
$0.02
N/AN/AN/AN/A
10 Best Cheap Stocks to Buy Now Cover

MarketBeat just released its list of 10 cheap stocks that have been overlooked by the market and may be seriously undervalued. Click the link below to see which companies made the list.

Get This Free Report

Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
Acer Therapeutics Inc. stock logo
ACER
Acer Therapeutics
0.00%0.00%0.00%0.00%-28.26%
AgeX Therapeutics, Inc. stock logo
AGE
AgeX Therapeutics
0.00%0.00%0.00%+4,200.24%+2,704.80%
Guardion Health Sciences, Inc. stock logo
GHSI
Guardion Health Sciences
+3.16%+1.24%-9.55%+42.98%+35.83%
Hoth Therapeutics, Inc. stock logo
HOTH
Hoth Therapeutics
-0.85%-1.69%-22.15%-16.55%-33.33%
Abliva AB (publ) stock logo
NEVPF
Abliva AB (publ)
0.00%0.00%0.00%-50.00%0.00%

MarketRank™

CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & Valuation
Acer Therapeutics Inc. stock logo
ACER
Acer Therapeutics
0.4515 of 5 stars
3.00.00.00.00.60.80.0
AgeX Therapeutics, Inc. stock logo
AGE
AgeX Therapeutics
N/AN/AN/AN/AN/AN/AN/AN/A
Guardion Health Sciences, Inc. stock logo
GHSI
Guardion Health Sciences
N/AN/AN/AN/AN/AN/AN/AN/A
Hoth Therapeutics, Inc. stock logo
HOTH
Hoth Therapeutics
2.5213 of 5 stars
3.55.00.00.02.50.00.6
Abliva AB (publ) stock logo
NEVPF
Abliva AB (publ)
N/AN/AN/AN/AN/AN/AN/AN/A

Analyst Ratings

CompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current Price
Acer Therapeutics Inc. stock logo
ACER
Acer Therapeutics
2.00
Hold$1.50127.24% Upside
AgeX Therapeutics, Inc. stock logo
AGE
AgeX Therapeutics
N/AN/AN/AN/A
Guardion Health Sciences, Inc. stock logo
GHSI
Guardion Health Sciences
2.00
HoldN/AN/A
Hoth Therapeutics, Inc. stock logo
HOTH
Hoth Therapeutics
3.00
Buy$4.00238.98% Upside
Abliva AB (publ) stock logo
NEVPF
Abliva AB (publ)
N/AN/AN/AN/A

Current Analyst Ratings

Latest ACER, GHSI, NEVPF, HOTH, and AGE Analyst Ratings

DateCompanyBrokerageActionRatingPrice TargetDetails
4/5/2024
Hoth Therapeutics, Inc. stock logo
HOTH
Hoth Therapeutics
HC Wainwright
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingBuy ➝ Buy$4.00
2/5/2024
Hoth Therapeutics, Inc. stock logo
HOTH
Hoth Therapeutics
HC Wainwright
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingBuy$4.00
2/2/2024
Guardion Health Sciences, Inc. stock logo
GHSI
Guardion Health Sciences
Maxim Group
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingBuy ➝ Hold
(Data available from 4/26/2021 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Sales & Book Value

CompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/Book
Acer Therapeutics Inc. stock logo
ACER
Acer Therapeutics
$1.26M12.81N/AN/A($1.05) per share-0.63
AgeX Therapeutics, Inc. stock logo
AGE
AgeX Therapeutics
$140K0.00N/AN/A($16.07) per share0.00
Guardion Health Sciences, Inc. stock logo
GHSI
Guardion Health Sciences
$12.25M0.83$0.14 per share57.36$6.39 per share1.24
Hoth Therapeutics, Inc. stock logo
HOTH
Hoth Therapeutics
N/AN/AN/AN/A$2.03 per shareN/A
Abliva AB (publ) stock logo
NEVPF
Abliva AB (publ)
N/AN/AN/AN/A$0.04 per shareN/A

Profitability & Earnings

CompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings Date
Acer Therapeutics Inc. stock logo
ACER
Acer Therapeutics
-$26.24M-$0.70N/AN/AN/AN/A-9.95%N/A
AgeX Therapeutics, Inc. stock logo
AGE
AgeX Therapeutics
-$14.80M-$13.03N/AN/AN/A-10,424.65%N/A-120.90%5/13/2024 (Estimated)
Guardion Health Sciences, Inc. stock logo
GHSI
Guardion Health Sciences
$160K$0.1171.82N/A0.51%2.01%1.21%5/20/2024 (Estimated)
Hoth Therapeutics, Inc. stock logo
HOTH
Hoth Therapeutics
-$7.84M-$4.77N/AN/AN/AN/A-76.28%-66.79%5/20/2024 (Estimated)
Abliva AB (publ) stock logo
NEVPF
Abliva AB (publ)
-$8.45MN/A0.00N/AN/A-63.75%-57.93%N/A

Latest ACER, GHSI, NEVPF, HOTH, and AGE Earnings

DateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails
3/28/2024Q4 2023
Guardion Health Sciences, Inc. stock logo
GHSI
Guardion Health Sciences
N/A$0.33+$0.33$0.33N/A$21.56 million

Dividends

CompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive Growth
Acer Therapeutics Inc. stock logo
ACER
Acer Therapeutics
N/AN/AN/AN/AN/A
AgeX Therapeutics, Inc. stock logo
AGE
AgeX Therapeutics
N/AN/AN/AN/AN/A
Guardion Health Sciences, Inc. stock logo
GHSI
Guardion Health Sciences
N/AN/AN/AN/AN/A
Hoth Therapeutics, Inc. stock logo
HOTH
Hoth Therapeutics
N/AN/AN/AN/AN/A
Abliva AB (publ) stock logo
NEVPF
Abliva AB (publ)
N/AN/AN/AN/AN/A

Debt

CompanyDebt-to-Equity RatioCurrent RatioQuick Ratio
Acer Therapeutics Inc. stock logo
ACER
Acer Therapeutics
N/A
0.10
0.02
AgeX Therapeutics, Inc. stock logo
AGE
AgeX Therapeutics
N/A
0.13
0.36
Guardion Health Sciences, Inc. stock logo
GHSI
Guardion Health Sciences
N/A
9.01
6.98
Hoth Therapeutics, Inc. stock logo
HOTH
Hoth Therapeutics
N/A
13.89
13.89
Abliva AB (publ) stock logo
NEVPF
Abliva AB (publ)
N/A
6.60
6.60

Ownership

Miscellaneous

CompanyEmployeesShares OutstandingFree FloatOptionable
Acer Therapeutics Inc. stock logo
ACER
Acer Therapeutics
3024.46 million19.96 millionNot Optionable
AgeX Therapeutics, Inc. stock logo
AGE
AgeX Therapeutics
51.08 million1.01 millionNot Optionable
Guardion Health Sciences, Inc. stock logo
GHSI
Guardion Health Sciences
91.28 million1.27 millionNot Optionable
Hoth Therapeutics, Inc. stock logo
HOTH
Hoth Therapeutics
24.89 million4.73 millionNot Optionable
Abliva AB (publ) stock logo
NEVPF
Abliva AB (publ)
8N/AN/ANot Optionable

ACER, GHSI, NEVPF, HOTH, and AGE Headlines

SourceHeadline
Probi ABProbi AB
barrons.com - March 20 at 6:04 PM
IVSXF Investor AB (publ)IVSXF Investor AB (publ)
seekingalpha.com - January 10 at 12:59 AM
Interfox Resources publ AB (IFOX)Interfox Resources publ AB (IFOX)
investing.com - October 3 at 12:53 AM
Oklahoma public higher ed leaders work to climb back from decade of cutsOklahoma public higher ed leaders work to climb back from decade of cuts
tulsaworld.com - March 19 at 7:57 PM
Orangeburg Department of Public Safety: Woman reports sexual assaultOrangeburg Department of Public Safety: Woman reports sexual assault
thetandd.com - March 18 at 5:23 PM
Resolutions at the Extraordinary General Meeting in Abliva AB (publ)Resolutions at the Extraordinary General Meeting in Abliva AB (publ)
privataaffarer.se - March 10 at 7:31 PM
Cell Impact publ AB (CELLI)Cell Impact publ AB (CELLI)
investing.com - October 14 at 7:21 AM
Abliva AB (publ) (NEVPF)Abliva AB (publ) (NEVPF)
nasdaq.com - January 20 at 8:12 PM

New MarketBeat Followers Over Time

Media Sentiment Over Time

Company Descriptions

Acer Therapeutics logo

Acer Therapeutics

NASDAQ:ACER
Acer Therapeutics Inc., a pharmaceutical company, focuses on the acquisition, development, and commercialization of therapies for serious rare and life-threatening diseases. The company's pipeline includes four clinical-stage candidates comprising EDSIVO for the treatment of vascular Ehlers-Danlos Syndrome in patients with a confirmed type III collagen mutation; ACER-801 for the treatment of induced Vasomotor Symptoms, post-traumatic stress disorder, and prostate cancer; and OLPRUVA, a formulation of sodium phenylbutyrate for the treatment of various inborn errors of metabolism, including urea cycle disorders and maple syrup urine disease. It has a license agreement with Sanofi to acquire worldwide rights to Osanetant, a clinical-stage, selective, and non-peptide tachykinin NK3 receptor antagonist; an option agreement with Relief for the development, regulatory approval, and commercialization of OLPRUVA; and an agreement with Emory University to acquire the worldwide intellectual property rights to a family of patents and patent applications related to the use of neurokinin receptor antagonists in managing conditioned fear and treating anxiety disorders, including post-traumatic stress disorder. The company was incorporated in 1991 and is headquartered in Newton, Massachusetts.
AgeX Therapeutics logo

AgeX Therapeutics

NYSE:AGE
AgeX Therapeutics, Inc., a biotechnology company, focuses on the development and commercialization of novel therapeutics targeting human aging and degenerative diseases in the United States. The company's lead cell-based therapeutic candidates in development include AGEX-BAT1, a cell therapy product candidate for the treatment of various age-related metabolic disorders, such as Type II adult-onset diabetes and obesity; and AGEX-VASC1, a cell-based therapy to restore vascular support in aged ischemic tissues, such as peripheral vascular disease and ischemic heart disease. Its lead small molecule drug-based therapeutic candidate for scarless wound repair in discovery is AGEX-iTR1547, a drug-based formulation; and lead biologic candidate for induced tissue regeneration is AGEX-iTR1550 (Renelon), a gene delivery technology. AgeX Therapeutics, Inc. has a research collaboration with the University of California at Irvine to develop cellular therapies to treat neurological disorders and diseases. The company was incorporated in 2017 and is based in Alameda, California.
Guardion Health Sciences logo

Guardion Health Sciences

NASDAQ:GHSI
Guardion Health Sciences, Inc., a clinical nutrition company, develops and distributes clinically supported nutrition, medical foods, and dietary supplements in North America and Europe, and Internationally. The company offers Lumega-Z, a medical food that replenishes and restores the macular protective pigment; and GlaucoCetin, a vision-specific medical food to support and protect the mitochondrial function of optic nerve cells, as well as improve blood flow in the ophthalmic artery in patients with glaucoma. It develops ImmuneSF, a nutraceutical formulation, as well as a portfolio of nutraceutical products under the NutriGuard brand. Further, it distributes medical foods products through e-commerce in an online store, guardionhealth.com. Guardion Health Sciences, Inc. was founded in 2009 and is headquartered in Houston, California.
Hoth Therapeutics logo

Hoth Therapeutics

NASDAQ:HOTH
Hoth Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on developing therapies for unmet medical needs. It is involved in the development of HT-001, a topical formulation, which is in Phase II clinical trial for the treatment of patients with rash and skin disorders associated with initial and repeat courses of tyrosine kinase epidermal growth factor receptor inhibitor therapy; HT-KIT to treat mast-cell derived cancers and anaphylaxis; HT-TBI to treat traumatic brain injury and ischemic stroke; HT-ALZ for the treatment and/or prevention of Alzheimer's or other neuroinflammatory diseases; HT-004 for treatment of asthma and allergies using inhalational administration; HT-003 for the treatment of acne and psoriasis, as well as inflammatory bowel diseases; and HT-002, a novel peptide for treating COVID-19. The company is also developing BioLexa Platform, a proprietary, patented, drug compound platform which is in Phase I clinical trial for the treatment of eczema; and HT-005 for treating patients with lupus, as well as a diagnostic device through a mobile device. The company has license agreements with the George Washington University; Isoprene Pharmaceuticals, Inc.; Virginia Commonwealth University; the North Carolina State University; Chelexa BioSciences, Inc. and the University of Cincinnati; Zylö Therapeutics, Inc.; and Voltron Therapeutics, Inc. It also has a research collaboration agreement with Weill Cornell Medicine to develop HT-003. Hoth Therapeutics, Inc. was incorporated in 2017 and is based in New York, New York.
Abliva AB (publ) logo

Abliva AB (publ)

OTCMKTS:NEVPF
Abliva AB (publ), a clinical-stage biotech company, develops medicines for the treatment of primary mitochondrial diseases. The company is developing KL1333 that is in Phase 2/3 clinical trials for the chronic treatment of primary mitochondrial diseases; NV354, which is in the preparation for clinical trials for the treatment of primary mitochondrial diseases with Complex I deficiency; and NeuroSTAT that is in Phase 1b/2a clinical study for traumatic brain injury. It has collaboration agreements with Isomerase, Yungjin Pharm, University of Pennsylvania, Children's Hospital of Philadelphia, and Oroboros Instruments. The company was formerly known as NeuroVive Pharmaceutical AB (publ) and changed its name to Abliva AB (publ) in May 2020. Abliva AB (publ) was incorporated in 2000 and is headquartered in Lund, Sweden.